Hypercholesterolaemia and its management
- Lipid disorders
- Metabolic disorders
- Drugs: cardiovascular system
- Ischaemic heart disease
their review about hypercholesterolaemia and its management Dr Bhatnager and his
coworkers declared that they had selected references from reviews if they
provided “a useful, objective, and comprehensive account including extensive
recent references.” By using this
method the authors have missed much important knowledge from the past. Let me
Hypercholesterolaemia was said to be one of the major causes of atherosclerosis. How come that no association between plasma cholesterol and degree of atherosclerosis has been found in post-mortem studies of unselected individuals?1-6 And how come that no angiographic trial has found exposure-response between degree of cholesterol lowering and outcome.7
A population was considered to be unhealthy when its average plasma cholesterol concentration exceeded 5 mmol/l. How come that almost all studies have shown that high cholesterol is not a risk factor for women?8 And how come that old people with high cholesterol live longer than old people with low?9-25 The latter is particularly curious because at least in Sweden more than 90% of all cardiovascular deaths occur in people above 65.
The optimal cholesterol concentration should be lower in patients with diabetes,. How come that numerous studies have found that high cholesterol is not a risk factor for diabetics?26-39
People with familial hypercholesterolaemia were said to be at a particular high risk. How come that in cohorts of such people, cholesterol is not associated with the incidence or prevalence of cardiovascular disease?40-47 And how come that these people’s risk of coronary heart disease is normal after age fifty, and that their average life span is similar to other people’s?48
A diet low in saturated fat was said to lower the risk of cardiovascular disease. How come that no randomised, controlled trial, where the only intervention was a lowering of cholesterol by dietary means has succeeded in lowering coronary or total mortality? How come that more than 20 cohort studies have found that patients with coronary heart disease have eaten the same amount of saturated fat as healthy controls?49,52 How come that almost all cohort studies have found that stroke patients have eaten less saturated fat than healthy controls?53-62 And how come that the concentration of the short-chain fatty acids in the tissues, the most reliable reflection of saturated fat intake,63-66 are not associated, or even inversely associated with coronary heart disease and degree of atherosclerosis?67-73
The authors cite a meta-analysis of 14 statin trials having shown that for each 1 mmol/l lowering of plasma LDL cholesterol, coronary and stroke events fell by about 21%. These figures were based on mean, not individual values. Curiously, no clinical or angiographic trial has found any association between degree of individual cholesterol lowering and outcome?7 There is a likely explanation, however.
If the benefit from the HMG-coenzyme A-inhibitors is due to their pleiotropic effects only, not to their inhibition of the cholesterol synthesis, a calculation using mean values should show exposure-response, also for degree of cholesterol lowering, whether cholesterol lowering by itself is useful or not. But even if the lowering of cholesterol is unimportant, there should also have been exposure-response for cholesterol for individual values because both the pleiotropic effects and cholesterol lowering are caused by inhibition of the mevalonate pathway; a more complete blockage should result in stronger pleiotropic effects and a more pronounced lowering of cholesterol, and vice versa. As this has not been the case in any trial, the only explanation is that some of the participants had a heart attack, although their cholesterol was lowered very much, and/or that some had no cardiovascular symptoms although their cholesterol was lowered very little, meaning that high cholesterol is protective. There is also much clinical and epidemiological evidence for that.74
No doubt, statin treatment may be of benefit, but the effect is grossly overstated. The figure 17% for instance is the relative percentage; no more than a few percent of those who are taken statins gain benefit, and only if they are high-risk patients.75 Little, if any effect has been seen for women and healthy people with normal or high cholesterol. Add also that the benefit may easily be outweighed by the side effects, because they are both much more serious and much more frequent than reported in the statin trials, if reported at all.75
A critical revision of the cholesterol campaign seems urgent, preferably performed by scientists without links to the drug industry.
1. Landé KE, Sperry WM. Human atherosclerosis in relation to the cholesterol content of the blood serum. Arch Pathol 1936;22: 301–12.
2. Paterson JC, Dyer L, Armstrong EC. Serum cholesterol levels in human atherosclerosis. Can Med Ass J 1960;82: 6–11.
3. Mathur KS, Patney NL, Kumar V, Sharma RD. Serum cholesterol and atherosclerosis in man. Circulation 1961;23: 847–52..
4. Marek Z, Jaegermann K, Ciba T. Atherosclerosis and levels of serum cholesterol in postmortem investigations. Am Heart J 1962; 63: 768–74.
5. Schwartz CJ, Stenhouse NS, Taylor AE, White TA.. Coronary disease severity at necropsy. Br Heart J 1965;27; 731-9..
6. Méndez J, Tejada C. Relationship between serum lipids and aortic atherosclerotic lesions in sudden accidental deaths in Guatemala City. Am J Clin Nutr 1967;20: 1113-7.
7. Ravnskov U. Is atherosclerosis caused by high cholesterol? QJM 2002;95: 397-403.
8. Jacobs D, Blackburn H, Higgins M, Reed D, Iso H, McMillan G, et al. Report of the conference on low blood cholesterol: mortality associations. Circulation 1992;86:1046–60.
9. Behar S, Graff E, Reicher-Reiss H, Boyko V, Benderly M, Shotan A, Brunner D. Low total cholesterol is associated with high total mortality in patients with coronary heart disease. The Bezafibrate Infarction Prevention (BIP) Study Group. Eur Heart J 1997;18: 52-9.
10. Casiglia E, Spolaore P, Ginocchio G, Colangeli G, Di Menza G, Marchioro M, et al. Predictors of mortality in very old subjects aged 80 years or over. Eur J Epidemiol 1993;9: 577-86.
11. Chyou PH, Eaker ED. Serum cholesterol concentrations and all-cause mortality in older people. Age Ageing 2000; 29:69-74.
12. Forette B, Tortrat D, Wolmark Y. Cholesterol as risk factor for mortality in elderly women. Lancet 1989;1: 868-70.
13. Fried LP, Kronmal RA, Newman AB, Bild DE, Mittelmark MB, Polak JF, et al. Risk factors for 5-year mortality in older adults: the Cardiovascular Health Study. JAMA 1998;279: 585-92.
14. Harris T, Feldman JJ, Kleinman JC, Ettinger WH Jr, Makuc DM, Schatzkin AG. The low cholesterol-mortality association in a national cohort. J Clin Epidemiol 1992;45: 595-601.
15. Jonsson A, Sigvaldason H, Sigfusson N. Total cholesterol and mortality after age 80 years. Lancet 1997; 350: 1778-9
16. Krumholz HM, Seeman TE, Merrill SS, Mendes de Leon CF, Vaccarino V, Silverman DI, er al. Lack of association between cholesterol and coronary heart disease mortality and morbidity and all-cause mortality in persons older than 70 years. JAMA 1994;272: 1335-40.
17. Räihä I, Marniemi J, Puukka P, Toikka T, Ehnholm C, Sourander L. Effect of serum lipids, lipoproteins, and apolipoproteins on vascular and nonvascular mortality in the elderly. Arterioscler Thromb Vasc Biol 1997;17: 1224-32.
18. Rudman D, Mattson DE, Nagraj HS, Caindec N, Rudman IW, Jackson DL. Antecedents of death in the men of a Veterans Administration nursing home. J Am Geriatr Soc 1987;35: 496-502.
19. Schatz IJ, Masaki K, Yano K, Chen R, Rodriguez BL, Curb JD. Cholesterol and all-cause mortality in elderly people from the Honolulu Heart Program: a cohort study. Lancet 2001;358: 351-5.
20. Schupf N, Costa R, Luchsinger J, Tang MX, Lee JH, Mayeux R. Relationship between plasma lipids and all-cause mortality in nondemented elderly. J Am Geriatr Soc 2005;53: 219-26.
21. Siegel D, Kuller L, Lazarus NB, Black D, Feigal D, Hughes G, et al. Predictors of cardiovascular events and mortality in the Systolic Hypertension in the Elderly Program pilot project. Am J Epidemiol 1987;126: 385-99.
22. Staessen J, Amery A, Birkenhager W, Bulpitt C, Clement D, de Leeuw P, et al. Is a high serum cholesterol level associated with longer survival in elderly hypertensives? J Hypertens 1990;8: 755-61.
23. Ulmer H, Kelleher C, Diem G, Concin H. Why Eve is not Adam: prospective follow-up in 149650 women and men of cholesterol and other risk factors related to cardiovascular and all-cause mortality. J Womens Health 2004;13: 41-53.
24. Weverling-Rijnsburger AW, Blauw GJ, Lagaay AM, Knook DL, Meinders AE, Westendorp RG. Total cholesterol and risk of mortality in the oldest old. Lancet 1997;350: 1119–23.
25. Akerblom JL, Costa R, Luchsinger JA, Manly JJ, Tang MX, Lee JH, et al. Relation of plasma lipids to all-cause mortality in Caucasian, African-American and Hispanic elders. Age Ageing. 2008;37: 207-13.
26. Fontbonne A, Eschwège E, Cambien F, Richard JL, Ducimetière P, Thibult N, et al. Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes. Results from the 11-year follow-up of the Paris Prospective Study. Diabetologia 1989;32: 300-4.
27. Uusitupa MI, Laakso M, Sarlund H, Majander H, Takala J, Penttilä I. Effects of a very-low-calorie diet on metabolic control and cardiovascular risk factors in the treatment of obese non-insulin-dependent diabetics. Am J Clin Nutr 1990;51: 768-73.
28. Fitzgerald AP, Jarrett RJ. Are conventional risk factors for mortality relevant in type 2 diabetes? Diabet Med 1991;8: 475-80.
29. Ford ES, DeStefano F. Risk factors for mortality from all causes and from coronary heart disease among persons with diabetes. Findings from the National Health and Nutrition Examination Survey I Epidemiologic Follow-up Study. Am J Epidemiol 1991;133: 1220-30.
30. Laakso M, Lehto S, Penttilä I, Pyörälä K. Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes. Circulation 1993;88, 1421-30.
31. Janghorbani M, Jones RB, Gilmour WH, Hedley AJ, Zhianpour M. A prospective population based study of gender differential in mortality from cardiovascular disease and "all causes" in asymptomatic hyperglycaemics. J Clin Epidemiol 1994;47: 397-405.
32. Collins VR, Dowse GK, Ram P, Cabealawa S, Zimmet PZ. Non-insulin-dependent diabetes and 11-year mortality in Asian Indian and Melanesian Fijians. Diabet Med 1996;13: 125-32.
33. Muggeo M, Verlato G, Bonora E, Zoppini G, Corbellini M, de Marco R. Long-term instability of fasting plasma glucose, a novel predictor of cardiovascular mortality in elderly patients with non-insulin-dependent diabetes mellitus: the Verona Diabetes Study. Circulation 1997;96: 1750-4.
34. Niskanen L, Turpeinen A, Penttilä I, Uusitupa MI. Hyperglycemia and compositional lipoprotein abnormalities as predictors of cardiovascular mortality in type 2 diabetes: a 15-year follow-up from the time of diagnosis. Diabetes Care 1998;21: 1861-9.
35. Hänninen J, Takala J, Keinänen-Kiukaanniemi S. Albuminuria and other risk factors for mortality in patients with non-insulin-dependent diabetes mellitus aged under 65 years: a population-based prospective 5-year study. Diabetes Res Clin Pract 1999;43: 121-6.
36. Forrest KY, Becker DJ, Kuller LH, Wolfson SK, Orchard TJ. Are predictors of coronary heart disease and lower-extremity arterial disease in type 1 diabetes the same? A prospective study. Atherosclerosis 2000;148: 159-69.
37. Ostgren CJ, Lindblad U, Melander A, Råstam L. Survival in patients with type 2 diabetes in a Swedish community: Skaraborg hypertension and diabetes project. Diabetes Care 2002;25: 1297-302.
38. Roselli della Rovere G, Lapolla A, Sartore G, Rossetti C, Zambon S, Minicuci N, et al. Plasma lipoproteins, apoproteins and cardiovascular disease in type 2 diabetic patients. A nine-year follow-up study. Nutr Metab Cardiovasc Dis 2003;13: 46-51..
39. Chan WB, Tong PC, Chow CC, So WY, Ng MC, Ma RC, et al. Triglyceride predicts cardiovascular mortality and its relationship with glycaemia and obesity in Chinese type 2 diabetic patients. Diabetes Metab Res Rev 2005;21: 183-8.
40. Miettinen TA, Gylling H. Mortality and cholesterol metabolism in familial hypercholesterolemia. Long-term follow-up of 96 patients. Arteriosclerosis 1988;8: 163-7.
41. Hill JS, Hayden MR, Frohlich J, Pritchard PH. Genetic and environmental factors affecting the incidence of coronary artery disease in heterozygous familial hypercholesterolemia. Arterioscler Thromb 1991;11: 290-7.
42. Ferrieres J, Lambert J, Lussier-Cacan S, Davignon J. Coronary artery disease in heterozygous familial hypercholesterolemia patients with the same LDL receptor gene mutation. Circulation 1995; 92: 290-5.
43. Kroon AA and others. J Intern Med 1995;238: 451-9.
44. Hopkins PN, Stephenson S, Wu LL, Riley WA, Xin Y, Hunt SE. Evaluation of coronary risk factors in patients with heterozygous famlial hypercholesterolema. Am J Cardiol 2001;87: 47-553.
45. de Sauvage Nolting PR, Defesche JC, Buirma RJ, Hutten BA, Lansberg PJ, Kastelein JJ. Prevalence and significance of cardiovascular risk factors in a large cohort of patients with familial hypercholesterolaemia. J Intern Med 2003;253: 161-8.
46. Neil HA, Seagroatt V, Betteridge DJ, Cooper MP, Durrington PN, Miller JP et al. Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia. Heart 2004;90: 1431-7.
47. Jansen AC, van Aalst-Cohen ES, Tanck MW, Cheng S, Fontecha MR, Li J, et al. Genetic determinants of cardiovascular disease risk in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2005;25: 1475-81.
48. Neil HA, Hawkins MM, Durrington PN, Betteridge DJ, Capps NE, Humphries SE; Simon Broome Familial Hyperlipidaemia Register Group and Scientific Steering Committee. Non-coronary heart disease mortality and risk of fatal cancer in patients with treated heterozygous familial hypercholesterolaemia: a prospective registry study.Atherosclerosis 2005; 179: 293-7.
49. Ravnskov U. The questionable role of saturated and polyunsaturated fatty acids in cardiovascular disease. J Clin Epidemiol 1998;51: 443-460.
50. Hooper L, Summerbell CD, Higgins JPT, Thompson RL, Capps NE, Smith GD et al. Dietary fat intake and prevention of cardiovascular disease: systematic review. BMJ 2001;322: 757–63.
51. Ravnskov U. Diet–heart disease hypothesis is wishful thinking. BMJ 2002; 324: 238.
52. Leosdottir M, Nilsson PM, Nilsson JA, Månsson H, Berglund G. Dietary fat intake and early mortality patterns--data from The Malmö Diet and Cancer Study. J Intern Med 2005;258: 153-165.
53. Stemmermann GN, Hayashi T, Resch JA, Chung CS, Reed DM, Rhoads GG. Risk factors related to ischemic and hemorrhagic cerebrovascular disease at autopsy: the Honolulu Heart Study. Stroke 1984; 15:23-28.
54. Takeya Y, Popper JS, Shimizu Y, Kato H, Rhoads GG, Kagan A. Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii and California: incidence of stroke in Japan and Hawaii. Stroke 1984;15, 15-23.
55. McGee D, Reed D, Stemmerman G, Rhoads G, Yano K, Feinleib M. The relationship of dietary fat and cholesterol to mortality in 10 years: the Honolulu Heart Program. Int J Epidemiol 1985;14: 97-105.
56. Gillman MW, Cupples LA, Millen BE, Ellison RC, Wolf PA. Inverse association of dietary fat with development of ischemic stroke in men. JAMA 1997;278: 2145-50.
57. Ross RK, Yuan JM, Henderson BE, Park J, Gao YT, Yu MC. Prospective evaluation of dietary and other predictors of fatal stroke in Shanghai, China. Circulation 1997;96: 50-5.
58. Seino F, Date C, Nakayama T, Yoshiike N, Yokoyama T, Yamaguchi M, Tanaka H. Dietary lipids and Incidence of cerebral infarction in a Japanese rural community. J Nutr Sci Vitaminol 1997;43: 83-99.
59. Iso H, Stampfer MJ, Manson JE, Rexrode K, Hu F, Hennekens CH, et al. Prospective study of fat and protein intake and risk of intraparenchymal hemorrhage in women. Circulation 2001;103: 856-63.
60. He K, Merchant A, Rimm EB, Rosner BA, Stampfer MJ, Willett WC, Ascherio A. Dietary fat intake and risk of stroke in male US healthcare professionals: 14 year prospective cohort study. BMJ 2003;327: 777-82.
61. Iso H, Sato S, Kitamura A, Naito Y, Shimamoto T, Komachi Y. Fat and protein intakes and risk of intraparenchymal hemorrhage among middle-aged Japanese. Am J Epidemiol 2003;157: 32-9
62. Sauvaget C, Nagano J, Hayashi M, Yamada M. Animal protein, animal fat, and cholesterol intakes and risk of cerebral infarction mortality in the adult health study. Stroke 2004;35: 1531-7.
63. Smedman AE, Gustafsson IB, Berglund LG, Vessby BO. Pentadecanoic acid in serum as a marker for intake of milk fat: relations between intake of milk fat and metabolic risk factors. Am J Clin Nutr 1999;69: 22-9.
64. Wolk A, Furuheim M, Vessby B. Fatty acid composition of adipose tissue and serum lipids are valid biological markers of dairy fat intake in men. J Nutr 2001;131: 828-33.
65. Rosell M, Johansson G, Berglund L, Vessby B, de Faire U, Hellenius ML. Associations between the intake of dairy fat and calcium and abdominal obesity. Int J Obes Relat Metab Disord 2004;28: 1427-34.
66. Brevik A, Veierod MB, Drevon CA, Andersen LF. Evaluation of the odd fatty acids 15:0 and 17:0 in serum and adipose tissue as markers of intake of milk and dairy fat. Eur J Clin Nutr 2005;59, 1417-22.
67. Hudgins LC, Hellerstein MK, Seidman CE, Neese RA, Tremaroli JD, Hirsch J. Relationship between carbohydrate-induced hypertriglyceridemia and fatty acid synthesis in lean and obese subjects. J Lipid Res 2000;41: 595-604.
68. Kirkeby K, Ingvaldsen P, Bjerkedal I. Fatty acid composition of serum lipids in men with myocardial infarction. Acta Med Scand 1972;192: 513-19.
69. Lang PD, Degott M, Heuck CC, Opherk D, Vollmar J. Fatty acid composition of adipose tissue, blood, lipids, and glucose tolerance in patients with different degrees of angiographically documented coronary arteriosclerosis. Res Exp Med 1982;180: 161-168.
70. Wood DA, Butler S, Riemersma RA, Thomson M, Oliver MF, Fulton M, et al. Adipose tissue and platelet fatty acids and coronary heart disease in Scottish men. Lancet 1984;2: 117-21.
71. Pedersen JI, Ringstad J, Almendingen K, Haugen TS, Stensvold I, Thelle DS. Adipose tissue fatty acids and risk of myocardial infarction--a case-control study. Eur J Clin Nutr 2000;54: 618-25.
72. Kark JD, Kaufmann NA, Binka F, Goldberger N, Berry EM. Adipose tissue n-6 fatty acids and acute myocardial infarction in a population consuming a diet high in polyunsaturated fatty acids.Am J Clin Nutr 2003;77, 796-802.
73. Clifton PM, Keogh JB, Noakes M. Trans fatty acids in adipose tissue and the food supply are associated with myocardial infarction. J Nutr 2004;134: 874-9.
74. Ravnskov U. High cholesterol may protect against infections and atherosclerosis. QJM 2003;96: 927-34.
75. Ravnskov U, Rosch PJ, Sutter MC, Houston MC. Should we lower cholesterol as much as possible?BMJ 2006;332:1330-2.
Competing interests: None declared
Competing interests: None declared
Magle Stora Kyrkogata 9, 22350 Lund, Sweden
Click to like: